Puma Biotechnology Inc (NASDAQ:PBYI) gapped up prior to trading on Tuesday . The stock had previously closed at $11.77, but opened at $10.73. Puma Biotechnology shares last traded at $9.81, with a volume of 1,989,765 shares.

Several equities research analysts have recently commented on PBYI shares. BidaskClub upgraded shares of Puma Biotechnology from a “strong sell” rating to a “sell” rating in a research note on Thursday, November 21st. Cowen reaffirmed a “hold” rating and set a $25.00 price objective on shares of Puma Biotechnology in a research report on Friday, August 9th. JPMorgan Chase & Co. reiterated a “sell” rating and issued a $13.00 price objective on shares of Puma Biotechnology in a research note on Monday, August 12th. Barclays decreased their target price on Puma Biotechnology from $9.00 to $6.00 and set an “underweight” rating for the company in a report on Thursday, November 7th. Finally, Citigroup set a $13.00 target price on Puma Biotechnology and gave the stock a “hold” rating in a research note on Monday, August 12th. Four research analysts have rated the stock with a sell rating and eight have given a hold rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $14.13.

The company has a market cap of $369.74 million, a price-to-earnings ratio of -3.29 and a beta of 1.68. The company has a current ratio of 1.71, a quick ratio of 1.67 and a debt-to-equity ratio of 6.84. The stock’s 50 day moving average price is $7.93 and its 200 day moving average price is $10.81.

Puma Biotechnology (NASDAQ:PBYI) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.32. Puma Biotechnology had a negative net margin of 33.90% and a negative return on equity of 325.89%. The firm had revenue of $56.40 million during the quarter, compared to the consensus estimate of $60.21 million. During the same period in the previous year, the firm earned $0.16 earnings per share. Puma Biotechnology’s revenue was down 9.9% compared to the same quarter last year. On average, equities analysts expect that Puma Biotechnology Inc will post -2.15 earnings per share for the current fiscal year.

A number of institutional investors have recently modified their holdings of the business. Nuveen Asset Management LLC bought a new stake in Puma Biotechnology in the second quarter worth about $7,716,000. Morgan Stanley raised its holdings in Puma Biotechnology by 273.6% in the second quarter. Morgan Stanley now owns 487,392 shares of the biopharmaceutical company’s stock valued at $6,194,000 after buying an additional 356,949 shares during the period. Point72 Asset Management L.P. lifted its position in Puma Biotechnology by 111.7% during the third quarter. Point72 Asset Management L.P. now owns 506,221 shares of the biopharmaceutical company’s stock valued at $5,449,000 after buying an additional 267,048 shares in the last quarter. Bogle Investment Management L P DE acquired a new position in Puma Biotechnology during the second quarter valued at approximately $3,342,000. Finally, Acadian Asset Management LLC lifted its position in Puma Biotechnology by 5,456.6% during the second quarter. Acadian Asset Management LLC now owns 254,714 shares of the biopharmaceutical company’s stock valued at $3,236,000 after buying an additional 250,130 shares in the last quarter. 92.68% of the stock is owned by hedge funds and other institutional investors.

Puma Biotechnology Company Profile (NASDAQ:PBYI)

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous).

Read More: Why are percentage gainers important?

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.